IARC Monographs Volume 100A Combined Estrogen–Progestogen Contraceptives

Supplementary Web Tables, Section 2, Cancer in Humans

These web tables formed part of the original submission and have been peer reviewed. They are posted as supplied by the Working Group. Readers are requested to report any errors to: edit-vol100A@iarc.fr.
Table 2.1Case–control studies of combined estrogen–progestogen contraceptives and breast cancer
Table 2.2 Summary of results from four studies of combined estrogen–progestogen contraceptives and breast cancer in carriers of BRCA1 and BRCA2 mutations
Table 2.3 Cohort studies of estrogen–progestogen contraceptives and endometrial cancer
Table 2.4 Case–control studies of combined estrogen–progestogen contraceptives and endometrial cancer
Table 2.5 Summary of results of meta-analysis of data from the International Collaboration of Epidemiological studies of Cervical Cancer (Appleby et al., 2007) on risk of invasive and in situ cervical carcinoma in relation to years of use and time since last use of combined estrogen–progestogen contraceptives
Table 2.6 Cohort studies of combined estrogen–progestogen contraceptives and ovarian cancer, 1981–2008
Table 2.7 Case–control studies of combined estrogen–progestogen contraceptives and ovarian cancer
Table 2.8 Case–control studies of combined estrogen–progestogen contraceptives and liver cancer
Table 2.9 Cohort studies of combined estrogen–progestogen contraceptives and cutaneous malignant melanoma
Table 2.10 Case–control studies of combined estrogen–progestogen contraceptives and malignant melanoma
Table 2.11 Cohort studies of combined estrogen–progestogen contraceptives and colorectal cancer
Table 2.12 Case–control studies of combined estrogen–progestogen contraceptives and colorectal cancer
Table 2.13 Case-control studies of combined estrogen–progestogen contraceptives and thyroid cancer
Table 2.14 Association between estrogen–progestogen contraceptives and other cancers